---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-000644"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2023-01-04T23:59:59+00:00"
generated_at: "2026-06-20T20:11:26.372431+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Collegium provides 2023 guidance: rev $565-580M, adj EBITDA $355-370M, $100M buyback

## Summary
- Product revenue net expected $565-580M for 2023, up from ~$460M in 2022.
- Adjusted EBITDA $355-370M, growing >4x rate of adjusted operating expenses ($135-145M).
- Board authorized $100M share repurchase program through December 31, 2023.
- Xtampza ER gross-to-net expected 61-63% in 2023, down from >65% previously.
- Federal Circuit upheld Belbuca patents, blocking Alvogen generic entry until 2032.

## SEC filing metadata
- accession: 0001104659-23-000644
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2023-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465923000644/0001104659-23-000644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465923000644/tm231443d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-000644
- JSON: https://secwatch.observer/filing/0001104659-23-000644.json
- Plain text: https://secwatch.observer/filing/0001104659-23-000644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.